Literature DB >> 9479495

Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family.

W Van Hul1, W Wuyts, J Hendrickx, F Speleman, J Wauters, K De Boulle, N Van Roy, P Bossuyt, P J Willems.   

Abstract

Two homologous genes, EXT1 and EXT2, responsible for the development of benign multiple cartilagenous bone tumors (exostoses) on the long bones, have been identified in the past 2 years. Several arguments have been provided to support the hypothesis that these genes have tumor suppressor activity and that loss of function of these genes may contribute to the development of bone tumors. The recent identification of two EXT-like genes, EXTL1 and EXTL2, homologous to the EXT genes and to each other, revealed the existence of a larger family of genes. We now report the identification of a homologous EST (EST01365), not derived from the known EXT and EXTL genes, indicating the existence of one additional member of this gene family. We characterized this third EXT-like gene, EXTL3, and compared it with the other four members of the EXT-EXTL family. In view of its putative tumor suppressor function, the EXTL3 gene can be considered a candidate gene for the breast cancer locus on chromosome 8p12-p22.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479495     DOI: 10.1006/geno.1997.5101

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  27 in total

1.  The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.

Authors:  C McCormick; G Duncan; K T Goutsos; F Tufaro
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 2.  The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.

Authors:  G Duncan; C McCormick; F Tufaro
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Genotype-phenotype correlation in hereditary multiple exostoses.

Authors:  C Francannet; A Cohen-Tanugi; M Le Merrer; A Munnich; J Bonaventure; L Legeai-Mallet
Journal:  J Med Genet       Date:  2001-07       Impact factor: 6.318

4.  Clinical characteristics of hereditary multiple exostoses: a retrospective study of mainland chinese cases in recent 23 years.

Authors:  Xue-Ling Guo; Yan Deng; Hui-Guo Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-02-06

5.  Gene expression analysis of primary normal human hepatocytes infected with human hepatitis B virus.

Authors:  Hyun Mi Ryu; Sung Gyoo Park; Sung Su Yea; Won Hee Jang; Young-Il Yang; Guhung Jung
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

6.  Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity.

Authors:  P K Cheung; C McCormick; B E Crawford; J D Esko; F Tufaro; G Duncan
Journal:  Am J Hum Genet       Date:  2001-06-05       Impact factor: 11.025

7.  Human tumor suppressor EXT gene family members EXTL1 and EXTL3 encode alpha 1,4- N-acetylglucosaminyltransferases that likely are involved in heparan sulfate/ heparin biosynthesis.

Authors:  B T Kim; H Kitagawa; J Tamura ; T Saito; M Kusche-Gullberg; U Lindahl; K Sugahara
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

8.  Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management.

Authors:  Liesbeth Hameetman; Judith Vmg Bovée; Antonie Hm Taminiau; Herman M Kroon; Pancras Cw Hogendoorn
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

Review 9.  Of hedgehogs and hereditary bone tumors: re-examination of the pathogenesis of osteochondromas.

Authors:  Kevin B Jones; Jose A Morcuende
Journal:  Iowa Orthop J       Date:  2003

10.  Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma.

Authors:  Abhirami Radhakrishnan; Nirmala Badhrinarayanan; Jyotirmay Biswas; Subramanian Krishnakumar
Journal:  Mol Vis       Date:  2009-10-22       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.